CJC-1295 questions answered without sales claims
Early blood-test findings are kept apart from unproved claims. Each answer gives the fact that matters for your choice.
The drug prompts your own growth gland
The company called ConjuChem created CJC-1295 so a brain order would last longer. Early tests showed longer growth hormone and IGF-1 effects, not better health.
CJC-1295 copies an order from the brain
The CJC-1295 drug repeats the brain's order for your growth gland. Scientists changed parts of that copy so your body would break it down more slowly [2].
The long CJC-1295 form also catches albumin, a protein in blood, with a hook called DAC. Albumin then carries the drug for several days [2].
CJC-1295 raises one hormone, then the liver makes another
The growth gland sends its own hormone out in bursts [3]. Next, your liver makes IGF-1 after receiving that hormone, a second hormone found on blood tests.
One shot kept growth hormone and IGF-1 high for several days in healthy adults [1]. The blood result didn't show that those adults became healthier.
CJC-1295 is not a steroid
The drug copies a growth-hormone order rather than acting as a steroid [2]. It asks your gland to release hormone already stored there.
Steroids work through your body's sex-hormone system. These studies measured growth hormone and IGF-1, not male sex hormones.
CJC-1295 ipamorelin names two drugs used together
Ipamorelin is a second lab-made drug that prompts the growth gland in another way [11]. Together the drugs might bring a bigger hormone release, but that result is not proof of better health.
Healthy adults have not been compared under set rules after receiving this exact pair. There is no proved treatment plan.
The drug lacks approval and is banned in tested sport
ConjuChem ended its work before CJC-1295 won approval. The short safety record and unfinished testing still matter.
The FDA has not approved CJC-1295 for people
CJC-1295 has no approval for human use anywhere. The FDA also won't let pharmacies use CJC-1295 as the main ingredient in a drug mixed for one patient.
An FDA group reviewed that use in 2024 and did not support it [13]. The small early studies had not settled safety.
A 2024 FDA group opposed pharmacy mixing
The group looked at CJC-1295 and other drugs that raise growth hormone. It raised concerns about the immune system and other possible harm from CJC-1295 [13].
In 2024, the group opposed using the drug as a main ingredient for pharmacy mixing. That ruling did not approve any form of care.
Tested athletes can lose the right to compete
The World Anti-Doping Agency sets drug rules for tested sports. It bans CJC-1295 at all times [15], both in and out of a contest.
Breaking the rule may bar an athlete from future contests. A lab also identified CJC-1295 in one product that had been seized [16].
FDA papers raised a possible immune reaction
A lab-made peptide may cause your body's defenses to attack it. FDA papers raised that concern for CJC-1295 in 2024 [13].
The papers don't say how often such a reaction happens. They flag an unanswered risk; they don't prove the earlier hormone studies harmed anyone.
The DAC hook makes the long form last longer
ConjuChem added a hook so the drug could attach to albumin, which travels in your blood. The name DAC means drug affinity complex and marks this long form.
CJC-1295 with DAC can attach to albumin
DAC names the small hook that catches albumin in blood [2]. That link lets the CJC-1295 long form remain for days.
Albumin carries the hooked peptide through your bloodstream. No-DAC has no hook, so albumin can't carry it along.
The rat and human studies found a much longer stay
In rats, CJC-1295 DAC caused about 4-fold more growth hormone release. After 72 hours, the drug was still present in blood tests [2].
In adults, half the drug was gone after 5.8 to 8.1 days [1]. Those times don't apply to no-DAC or establish safe timing for you.
Human CJC-1295 DAC studies based amounts on weight
Human studies used one shot of 30-90 micrograms per kilogram under the skin. The CJC-1295 long form then remained much longer [1][3].
One microgram is a millionth part of one gram; per kilogram ties the amount to body weight. The figures describe the study, not a safe dose.
Other early studies also gave one shot
The researchers also used 30, 60 or 90 micrograms per kilogram [1][3]. They watched what happened to blood hormones afterward.
There is no approved amount for treating an illness. Fixed plans online didn't come from studies that compared treatment groups [7].
Study methods do not make the drug safe at home
ConjuChem's researchers handled the peptide with care in a lab. Those steps don't turn CJC-1295 into an approved home treatment.
The lab workers used germ-free water
The workers mixed the dry peptide powder with germ-free water, then stored the mixture cold [1]. That tells you what happened in the lab.
CJC-1295 isn't approved for you or anyone else. A lab step can't make home use safe.
The study put CJC-1295 under the skin
The study used an injection into the fatty layer below the skin [1]. That fact only tells how researchers gave the drug.
No agency has approved the drug for human use. A study method isn't a direction for you.
Human studies haven't set a CJC-1295 ipamorelin amount
Human studies have not set an amount for the CJC-1295/ipamorelin pair [11]. The two drugs prompt the growth gland in different ways.
That difference explains why scientists want to study them together. Numbers from online posts can't tell you what amount is safe.
CJC-1295 ipamorelin hasn't proved a health gain
Together, the two drugs might produce a larger hormone release than either drug alone [11]. More growth hormone or IGF-1 doesn't mean better health.
No human study comparing groups has proved a benefit for this exact pair [11]. The answer is still missing.
No one can yet call CJC-1295 safe
There is no large human safety study. The DAC plan stopped, while questions remain about swelling and links between IGF-1 and cancer [13][14].
The FDA also raised an immune-system concern. CJC-1295 is still unapproved [7].
CJC-1295 has no safety record over years
Only small early human studies have been published. Long follow-up is missing, and the DAC testing plan stopped [13][7].
The FDA later raised a possible immune reaction. That later warning doesn't prove that the earlier hormone work caused harm.
CJC-1295 studies didn't answer the testosterone question
The drug works through growth hormone, not your body's controls for testosterone [2]. The researchers measured growth hormones instead of male sex hormones [3].
They weren't testing CJC-1295 as a testosterone drug. Claims of either a rise or a drop go beyond their work.
Studies haven't counted CJC-1295 side effects well
No study comparing groups counted harm in healthy adults [7]. A growth-hormone rise may bring swelling and leave insulin less able to clear sugar from blood.
Higher IGF-1 has links with some cancers. The FDA raised a separate immune concern, and no long study has settled either question [13][14].
Early CJC-1295 studies found only blood changes
After one shot, growth hormone rose several times from its starting point. That is a study result, not a reason to use the drug.
IGF-1 rose by about 45%, and the change lasted for days [3]. Outside a planned study, you do not know the likely benefit, the size of a hormone change, or the chance of harm from the drug.
No study reports that CJC-1295 lowers testosterone
No published CJC-1295 study found lower testosterone [2][3]. Those studies measured growth hormone and IGF-1 instead.
Their work backs neither a claim of a rise nor a claim of a drop. The testosterone question remains open.